Key Resources

ASGE Guidelines

ASGE evidence-based guidelines provide clinicians with recommendations for the evaluation, diagnosis, and management of patients undergoing endoscopic procedures of the digestive tract. Guidelines are not a substitute for physicians’ opinion on individual patients. Final decision on an intervention should always be based on local expertise and patient preferences.

All recommendations follow a rigorous process based on a systematic review of medical literature as outlined by the National Academy of Medicine (formerly Institute of Medicine) standards for guideline development.

Whenever possible, guidelines are based on the GRADE (Grading of Recommendation Assessment, Development and Evaluation) methodology.

Panels consist of content experts, stakeholders from other specialties, patient representatives, and members of the ASGE Standards of Practice (SOP) Committee.

Each recommendation is based on consideration of the best medical literature, the balance between risks and benefits, cost-effectiveness, patients’ values, and equity.

Panel members provide ongoing conflict of interest (COI) disclosures, including intellectual conflicts of interest, throughout the development and publication of all guidelines in accordance with the ASGE Policy for Managing Declared Conflicts of Interests.

ASGE strives to provide clinically relevant and practical recommendations, which can help standardize patient care and improve outcomes.

If you have any questions or suggestions, please contact Customer Support at Info@asge.org.

The following information is intended only to provide general information and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult your doctor about your specific condition.

Newly Published

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
GRADE Guidelines

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Upper GI

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Lower GI

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Biliary and Pancreatic Endoscopy

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Adverse Events

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Privileging and Credentialing

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
GI Endoscopy Unit Operations

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Screening and Surveillance in Premalignant Conditions

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Procedural Management in Endoscopy

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Miscellaneous

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement
Guidelines in Spanish

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement

In Progress Guidelines

ASGE Guideline on the role of endoscopy in the diagnosis of indeterminate bile duct strictures

2023

ASGE Guideline on management of code status in the periendoscopic period

Estimated 2023

Quality in Endoscopy

Quality documents define the indicators of high-quality endoscopy and how to measure it. ASGE quality indicators are based on a rigorous review process which results in valid metrics for evaluating GI endoscopic procedures. 

Quality in Endoscopy

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Nov 14, 2016, 20:27 PM
Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonoscopy therefore is recommended to detect dysplasia. Detection of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia. Current U.S. guidelines recommend obtaining at least 32 random biopsy specimens from all segments of the colon as the foundation of endoscopic surveillance.1-4 However, much of the evidence that provides a basis for these recommendations is from older literature, when most dysplasia was diagnosed on random biopsies of colon mucosa.5 With the advent of video endoscopy and newer endoscopic technologies, investigators now report that most dysplasia discovered in patients with inflammatory bowel disease (IBD) is visible.6,7 Such a paradigm shift may have important implications for the surveillance and management of dysplasia.
Title : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
Doi org link : http://dx.doi.org/10.1016/j.gie.2014.12.009
Volume : Gastrointest Endosc 2015;81:489–501.e26
URL : /docs/default-source/importfiles/publications_(public)/practice_guidelines/scenic_consensus_statement.pdf?Status=Master&sfvrsn=2
Select a choice : Keep
Content created : Oct 15, 2014, 04:05 AM
File size :
Number :
ExternalPK : 17594
Categories :
  • Endoscopy in Inflammatory Bowel Disease
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
Tags :
SCENIC_consensus_statement

Technology Assessments

Technology evaluations provide a review of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Evaluations are based on a literature review and a search of the MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database to identify the reported adverse events of a given technology. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided.

Technology Assessments